CA2248809A1 - N-[(r)-1-{3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine utilisee comme antagoniste du recepteur du fibrinogene - Google Patents

N-[(r)-1-{3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine utilisee comme antagoniste du recepteur du fibrinogene Download PDF

Info

Publication number
CA2248809A1
CA2248809A1 CA002248809A CA2248809A CA2248809A1 CA 2248809 A1 CA2248809 A1 CA 2248809A1 CA 002248809 A CA002248809 A CA 002248809A CA 2248809 A CA2248809 A CA 2248809A CA 2248809 A1 CA2248809 A1 CA 2248809A1
Authority
CA
Canada
Prior art keywords
compound
salt
formula
acid
alanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002248809A
Other languages
English (en)
Inventor
Mitsuru Ohkubo
Fumie Takahashi
Toshio Yamanaka
Masayuki Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ZA962033A external-priority patent/ZA962033B/xx
Application filed by Individual filed Critical Individual
Publication of CA2248809A1 publication Critical patent/CA2248809A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

Dérivé de .beta.-alanine représenté par la formule (I). Ce dérivé est un antagoniste de la glycoprotéine IIB/IIIa, un inhibiteur de l'agrégation des plaquettes sanguines et un inhibiteur de la liaison du fibrinogène aux plaquettes sanguines. L'invention porte également sur des procédés d'élaboration de ce dérivé, sur une composition pharmaceutique le renfermant et sur une méthode de prévention et/ou de traitement de maladies indiquées dans la description de l'invention, chez l'être humain et l'animal.
CA002248809A 1996-03-13 1997-03-12 N-[(r)-1-{3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine utilisee comme antagoniste du recepteur du fibrinogene Abandoned CA2248809A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA96/2033 1996-03-13
ZA962033A ZA962033B (en) 1995-03-17 1996-03-13 New compound

Publications (1)

Publication Number Publication Date
CA2248809A1 true CA2248809A1 (fr) 1997-09-18

Family

ID=65952245

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002248809A Abandoned CA2248809A1 (fr) 1996-03-13 1997-03-12 N-[(r)-1-{3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine utilisee comme antagoniste du recepteur du fibrinogene

Country Status (5)

Country Link
EP (1) EP0888302A1 (fr)
JP (1) JP2000506524A (fr)
KR (1) KR19990087694A (fr)
CA (1) CA2248809A1 (fr)
WO (1) WO1997033869A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066651A (en) 1997-10-29 2000-05-23 Ortho-Mcneil Pharmaceutical, Inc. Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders
AUPP646598A0 (en) 1998-10-12 1998-11-05 Fujisawa Pharmaceutical Co., Ltd. New processes for producing alpha-alanine derivative
AU769718B2 (en) * 1998-10-12 2004-02-05 Fujisawa Pharmaceutical Co., Ltd. New processes for producing beta-alanine derivative
BR0010652A (pt) * 1999-03-22 2002-07-16 Ortho Mcneil Pharm Inc Processo de preparação de ácido [s-(r*,s*)]-beta-[[[1-[1-oxo-3-(4-piperidinil)propil]-3-piperi dinil]carbonil]amino]-3-piridinapropanóico e derivados
JP2001131078A (ja) * 1999-11-09 2001-05-15 Iatron Lab Inc 新規活性固定化血小板及びその製造方法
AUPQ570100A0 (en) * 2000-02-17 2000-03-09 Fujisawa Pharmaceutical Co., Ltd. Beta-alanine derivatives and their use as receptor antagonists
EP1719529A4 (fr) * 2004-02-25 2008-05-21 Astellas Pharma Inc Produit de contraste pour la formation d'un thrombus
US9345793B2 (en) 2011-08-17 2016-05-24 Piramal Imaging Sa Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombi
CN105189521A (zh) 2013-02-12 2015-12-23 拜耳医药股份公司 结合至血小板特异性糖蛋白IIb/IIIa的金属螯合化合物
KR102548998B1 (ko) 2020-03-31 2023-06-29 재단법인 아산사회복지재단 혈전영상을 위한 방사성의약품 및 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2037153A1 (fr) * 1990-03-09 1991-09-10 Leo Alig Derives de l'acide acetique
WO1992019595A1 (fr) * 1991-05-07 1992-11-12 Merck & Co., Inc. Antagonistes de recepteur de fibrinogene
EP0669912B1 (fr) * 1993-09-22 2001-12-05 Fujisawa Pharmaceutical Co., Ltd. Derives de n-(3-piperidinylcarbonyl)-beta-alanine utilises comme antagonistes du facteur d'agregation plaquettaire
WO1995011228A1 (fr) * 1993-10-19 1995-04-27 Sumitomo Pharmaceuticals Co., Ltd. Derive d'acide 2,3-diaminopropionique
US5770575A (en) * 1994-03-16 1998-06-23 Ortho Pharmaceutical Corporation Nipecotic acid derivatives as antithrombotic compounds
KR19980703107A (ko) * 1995-03-17 1998-10-15 후지야마 아키라 N-아실피페리디닐카보닐아미노카복실산 및 당단백질 IIB/IIa 길항제와 피브리노겐-혈소판 결합 억제제로서의 이의 용도

Also Published As

Publication number Publication date
EP0888302A1 (fr) 1999-01-07
KR19990087694A (ko) 1999-12-27
JP2000506524A (ja) 2000-05-30
WO1997033869A1 (fr) 1997-09-18

Similar Documents

Publication Publication Date Title
EP1025106B1 (fr) Modulateurs allosteriques des recepteurs de l'adenosine
US8268828B2 (en) Inhibitors of the chemokine receptor CxCR3
US6232290B1 (en) Cyclic hexapeptides with antimicrobial activity
US6323214B1 (en) Allosteric adenosine receptor modulators
EP0879227A1 (fr) Derives de tyrosine utilises comme inhibiteurs d'alpha-v-integrine
CA2248809A1 (fr) N-[(r)-1-{3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine utilisee comme antagoniste du recepteur du fibrinogene
EP1278730B1 (fr) 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol
AU2016245418B2 (en) Novel pyridinium compounds
EP1124824B1 (fr) Derives de chromenone et de chromanone utilises comme inhibiteurs d'integrine
US20010016571A1 (en) N-[ (R) -1-{3- (4- piperidyl) propionyl } -3-piperidylcarbonyl] -2 (S) -acetylamino-beta -alanine as fibrinogen receptor antagonist
US6602905B1 (en) N-acyl homoserine lactones for the treatment of cardiac tachyarrhythmias, ischaemic heart disease or congestive heart failure
CA2215106A1 (fr) Acides n-acylpiperidinylcarbonylaminocarboxyliques et leur utilisation en tant qu'antagonistes de la glycoproteine iib/iiia et inhibiteurs de liaison du fibrinogene et des plaquettes sanguines
CA2268590A1 (fr) Composes de regulation des canaux ioniques et utilisations de ces produits
EP1483285B1 (fr) INHIBITEURS DU FACTEUR DE COAGULATION Xa, LEUR PRODUCTION ET LEUR UTILISATION
US6538007B1 (en) N-[(R)-1-[3-(4-piperidyl)propionyl]-3-piperidylcarbonyl]-2(S)-acetylamino-β-alanine trihydrate, compositions thereof, and methods for its use
EP1290010A1 (fr) Pyridin-2-yl-aminoalkylcarbonylglycyl-$g(b)-alanine et ses derives
KR890002085B1 (ko) 디히드로오로트산 유도체의 제조방법
OA12180A (en) Cyclic hexapeptide derivatives.
EP0285323B1 (fr) Agents antiarythmiques
US5952299A (en) Cyclic peptide nuclei and derivatives thereof
DE19653036A1 (de) Cyclopeptidderivate
RU1063059C (ru) Гидрохлориды производных 2-карбэтокси-4-оксибензофурана, обладающие противоаритмической и противофибрилл торной активностью
KR100295353B1 (ko) 베타-알라닌유도체및이의제조방법
WO2000063178A1 (fr) Derives de dibenzoazulene pour le traitement de la thrombose, de l'osteoporose et de l'arteriosclerose
JPH08277285A (ja) ピペリジン化合物、その製造法およびその用途

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead